Clinical Trials on Immunoproliferative Disorders

Total 144583 results

Sun Yat-sen University
China Food and Drug Administration

Recruiting

PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma

Treatment Refusal

China
ImmuneOncia Therapeutics Inc.

Completed

A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

Lymphoma | Solid Tumor

Korea, Republic of, United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC; Syndax Pharmaceuticals

Active, not recruiting

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Lymphoma | Refractory | Relapsed

United States
University College, London
The Christie NHS Foundation Trust

Active, not recruiting

PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma (RAPID)

Lymphoma

United Kingdom
National Cancer Institute (NCI)

Completed

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

Lymphoma | Solid Tumors

United States
AbbVie
I-Mab Biopharma Co. Ltd.

Completed

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Lymphoma | Solid Tumor

United States, China
PharmaMar

Terminated

A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma

Lymphoma | Solid Tumors

United States
Peking Union Medical College Hospital

Unknown

TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial

Multicentric Castleman Disease

China
NantBioScience, Inc.

Withdrawn

QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas

Neoplastic Disease

United States
Millennium Pharmaceuticals, Inc.

Completed

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

Lymphoma | Solid Tumors

United States
AEterna Zentaris

Completed

Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas

Tumors | Lymphomas
Celgene

Completed

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma

Cancer | Lymphomas

United States
Millennium Pharmaceuticals, Inc.

Completed

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

Lymphoma | Nonhematologic Malignancies

United States
Children's Oncology Group
National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe...

Completed

TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma

Lymphoma | Leukemia

France, United Kingdom
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Phase I Study of Mitoxantrone Hydrochloride Liposome Injection

Malignant Lymphoma

China
Lymphoma Trials Office

Unknown

Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom
St Stephens Aids Trust

Unknown

Evolution of Cellular and Viral Resistance in HIV-infected Patients With Lymphoma (SSAT042)

Lymphoma | HIV

United Kingdom
Cooperative Study Group A for Hematology

Unknown

Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma

Lymphoma

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Recruiting

Study of Autoimmune Lymphoproliferative Syndrome (ALPS)

Benign Lymphoproliferative Disorder

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Multicenter Randomized Double-blind Study Comparing the Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis) (TRIBECA)

Vasculitis | Cryoglobulinemia
Sichuan University

Recruiting

Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL

Leukemia, Lymphoid

China
Stanford University
Bass Center Leukemia Pilot Grant; Pediatric Oncology Experimental Therapeutics...

Not yet recruiting

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

Lymphoid Leukemia

United States
Royal Marsden NHS Foundation Trust

Not yet recruiting

CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study (CLIMB)

CNS Lymphoma

United Kingdom
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

Lymphoma

China
HitGen Inc.

Recruiting

Clinical Trial of HG146 Administered to Subjects With Advanced Solid Tumors or Lymphoma

Lymphoma | Solid Tumor

China
Da Zen Theranostics Inc

Recruiting

A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma

Lymphoma | Solid Tumor

United States
University Hospital, Strasbourg, France

Recruiting

Leukemic Phase of ALCL (LEUK-ALCL)

Anaplastic Lymphoma

France
University Hospital Heidelberg

Recruiting

Registry Study of Proton Radiotherapy in Lymphoma

Mediastinal Lymphoma

Germany
University College, London
Roche Pharma AG; Cancer Research UK

Completed

Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Lymphoma

New Zealand, United Kingdom, Australia
European Organisation for Research and Treatment...

Active, not recruiting

Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

Lymphoma
Sheba Medical Center

Active, not recruiting

TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma (TEAM)

Malignant Lymphoma

Israel
University of Michigan Rogel Cancer Center
Bristol-Myers Squibb; Bayer; University of Michigan; Big Ten Cancer Research Consortium

Active, not recruiting

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Indolent Lymphoma

United States
Shanghai Jiatan Pharmatech Co., Ltd

Completed

A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma

Advanced Cancer

China
Merck Sharp & Dohme LLC

Completed

Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)

Lymphoma | Solid Tumor

United States, Israel
CStone Pharmaceuticals

Completed

A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

Lymphoma | Solid Tumor

China
Jennifer Amengual
Acetylon Pharmaceuticals Incorporated

Completed

ACY-1215 for Relapsed/Refractory Lymphoid Malignancies

Lymphoma | Lymphoid Malignancies

United States
M.D. Anderson Cancer Center

Terminated

Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

Lymphoma

United States
Chinese PLA General Hospital

Unknown

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Lymphoma | Solid Tumor

China
Dong-A ST Co., Ltd.

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients

Lymphoma | Solid Tumor

Korea, Republic of
Eli Lilly and Company

Terminated

A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma (JZAR)

Lymphoma | Advanced Cancer

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)

Lymphoma
Aalborg University Hospital
Turku University Hospital; Oslo University Hospital; Helsinki University Central... and other collaborators

Terminated

Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma (SCF980266)

Malignant Lymphoma

Denmark, Sweden, Finland, Norway
MedImmune LLC

Terminated

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Lymphoma | Leukemia | Cancer

United States
University Health Network, Toronto

Recruiting

Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial

Epstein-Barr Virus Infections | Post-transplant Lymphoproliferative Disorder

Canada
Cell Medica Ltd

Terminated

Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (CIVIC)

Lymphoma, Large B-Cell, Diffuse | Hodgkin Lymphoma | Post-transplant Lymphoproliferative Disorder

United States
National Institute of Allergy and Infectious Diseases...

Completed

Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome

Autoimmune Disease | Lymphoproliferative Disorder

United States
McGill University
McGill University Health Centre/Research Institute of the McGill University... and other collaborators

Completed

Feasibility, Acceptability, and Preliminary Effects of Lymfit (Lymfit)

Lymphoma | Cancer Survivors

Canada
European Organisation for Research and Treatment...
UNICANCER; Lymphoma Study Association

Active, not recruiting

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Lymphoma

France, Spain, Switzerland, Netherlands, Belgium, Poland, Slovenia, Italy, Slovakia, Portugal
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Autologous Transplant in HIV Patients (BMT CTN 0803)

Lymphoma | HIV

United States
Canwell Biotech Limited

Not yet recruiting

Intratumoral CAN2109 in Subjects With Solid Tumors or Lymphomas

Lymphoma | Solid Tumor

China

Clinical Trials on Immunoproliferative Disorders

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations